ADPORT

This brand name is authorized in Austria, Finland, Netherlands.

Active ingredients

The drug ADPORT contains one active pharmaceutical ingredient (API):

1	Tacrolimus UNII WM0HAQ4WNM - TACROLIMUS
	Tacrolimus is a highly potent immunosuppressive agent. In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ-interferon) and the expression of the interleukin-2 receptor.
	Read more about Tacrolimus

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AD02	Tacrolimus	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AD Calcineurin inhibitors
Discover more medicines within L04AD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FI	Lääkealan turvallisuus- ja kehittämiskeskus	049301, 059757, 114502, 402253, 577142
NL	Z-Index G-Standaard, PRK	197165, 92363, 92371, 92398